Company: ABUS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001447028-25-000126
Chunk: 30

Company: Arbutus Biopharma Corp
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 30
---
 measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:Level 1Level 2Level 3TotalAs of September 30, 2025(in thousands)AssetsCash and cash equivalents$22,408 $— $— $22,408 Investments in marketable securities, current— 71,294 — 71,294 Total$22,408 $71,294 $— $93,702 LiabilitiesContingent consideration$— $— $11,052 $11,052 Total$— $— $11,052 $11,052 Level 1Level 2Level 3TotalAs of December 31, 2024(in thousands)AssetsCash and cash equivalents$36,330 $— $— $36,330 Investments in marketable securities, current— 86,293 — 86,293 Total$36,330 $86,293 $— $122,623 LiabilitiesContingent consideration$— $— $10,225 $10,225 Total$— $— $10,225 $10,225 The following table presents the changes in fair value of the Company’s contingent consideration:  Liability at beginning of the periodChange in fair value of liabilityLiability at end of the period(in thousands)Nine Months Ended September 30, 2025$10,225 $827 $11,052 Nine Months Ended September 30, 2024$7,600 $735 $8,335 

See Note 4 for additional information regarding the fair value of the Company’s investments in marketable securities. 

 9

4.    Investments in marketable securities 

Investments in marketable securities consisted of the following:Amortized CostGross Unrealized Gain(1)Gross Unrealized Loss(1)Fair ValueAs of September 30, 2025(in thousands)Cash equivalentsMoney market funds$7,838 $— $— $7,838 Total$7,838 $— $— $7,838 Investments in marketable short-term securitiesUS corporate bonds$3,059 $3 $— $3,062 US treasury bills37,981 31